Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

By L. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai, K. Reuter, M. Meng, D. Fritz, F. Vascotto, Hossam Hefesha and 18 more. Nature, 2016

1,560 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “The liposome formulation protects the RNA from early degradation and facilitates uptake by APCs, where the RNA is translated into four antigen encoding proteins, thus the nano-vaccine targets four different tumor-associated antigens [184].”
Neoantigens: promising targets for cancer therapy (2023, background): “Advanced RNA-lipoplex formulations have been developed and explored as therapeutic cancer vaccines in several clinical studies owing to their advantage in systemic DC targeting and synchronized induction of highly potent adaptive and innate immune responses (NCT02410733, NCT02316457).(345,346) Anoth”
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. (2019, neutral): “11 Conversely, Kranz et al. 174 reported that intravenous (i.v.) injection of unmodi ﬁ ed mRNA-lipid complexes raised T cell stimulation through TLR 7-mediated activation of type I IFN.”
mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “vaccination (NCT02035956)(366) and exploited LNP to generate an anti-melanoma mRNA vaccine, which attributed to regression of a suspected metastasis in an intravenously vaccinated patient (NCT02410733).(367) Due to the inconsistent data, further research may help confirm that mRNA vaccines can serve”